Selected research
Industry Research
Alpha Synuclein Industry Research Report 2026
Market perspective
The global Alpha Synuclein market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Alpha Synuclein is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Alpha Synuclein is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Alpha Synuclein is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Alpha Synuclein include Biogen Inc, reMYND NV, QR Pharma Inc, Prothena Corp Plc, nLife Therapeutics SL, Neuropore Therapies Inc, MedImmune LLC, ICB International Inc and H. Lundbeck A/S, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Alpha Synuclein market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Alpha Synuclein Market by Company
Biogen Inc
reMYND NV
QR Pharma Inc
Prothena Corp Plc
nLife Therapeutics SL
Neuropore Therapies Inc
MedImmune LLC
ICB International Inc
H. Lundbeck A/S
Genmab A/S
Evotec AG
BioArctic AB
AFFiRiS AG
AC Immune SA
Alpha Synuclein Segment by Type
DPC-003
BIIB-054
BAN-0805
AV-1950R
AV-1947D
Others
Alpha Synuclein Segment by Application
Multiple System Atrophy
Lewy Body Dementia
Neurodegenerateive Disease
Others
Alpha Synuclein Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Alpha Synuclein market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Alpha Synuclein and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Alpha Synuclein.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Alpha Synuclein manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Alpha Synuclein by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Alpha Synuclein in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- DPC-003
- BIIB-054
- BAN-0805
- AV-1950R
- AV-1947D
- Others
Applications
- Multiple System Atrophy
- Lewy Body Dementia
- Neurodegenerateive Disease
- Others
Companies covered
- Biogen Inc
- reMYND NV
- QR Pharma Inc
- Prothena Corp Plc
- nLife Therapeutics SL
- Neuropore Therapies Inc
- MedImmune LLC
- ICB International Inc
- H. Lundbeck A/S
- Genmab A/S
- Evotec AG
- BioArctic AB
- AFFiRiS AG
- AC Immune SA
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Alpha Synuclein Market Size (2021-2032)
- 2.2.2 Global Alpha Synuclein Sales (2021-2032)
- 2.2.3 Global Alpha Synuclein Market Average Price (2021-2032)
- 2.3 Alpha Synuclein by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 DPC-003
- 2.3.3 BIIB-054
- 2.3.4 BAN-0805
- 2.3.5 AV-1950R
- 2.3.6 AV-1947D
- 2.3.7 Others
- 2.4 Alpha Synuclein by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Multiple System Atrophy
- 2.4.3 Lewy Body Dementia
- 2.4.4 Neurodegenerateive Disease
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Alpha Synuclein Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Alpha Synuclein Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Alpha Synuclein Revenue of Manufacturers (2021-2026)
- 3.4 Global Alpha Synuclein Average Price by Manufacturers (2021-2026)
- 3.5 Global Alpha Synuclein Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Alpha Synuclein, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Alpha Synuclein, Product Type & Application
- 3.8 Global Manufacturers of Alpha Synuclein, Established Date
- 3.9 Global Alpha Synuclein Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Biogen Inc
- 4.1.1 Biogen Inc Company Information
- 4.1.2 Biogen Inc Business Overview
- 4.1.3 Biogen Inc Alpha Synuclein Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Biogen Inc Alpha Synuclein Product Portfolio
- 4.1.5 Biogen Inc Recent Developments
- 4.2 reMYND NV
- 4.2.1 reMYND NV Company Information
- 4.2.2 reMYND NV Business Overview
- 4.2.3 reMYND NV Alpha Synuclein Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 reMYND NV Alpha Synuclein Product Portfolio
- 4.2.5 reMYND NV Recent Developments
- 4.3 QR Pharma Inc
- 4.3.1 QR Pharma Inc Company Information
- 4.3.2 QR Pharma Inc Business Overview
- 4.3.3 QR Pharma Inc Alpha Synuclein Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 QR Pharma Inc Alpha Synuclein Product Portfolio
- 4.3.5 QR Pharma Inc Recent Developments
- 4.4 Prothena Corp Plc
- 4.4.1 Prothena Corp Plc Company Information
- 4.4.2 Prothena Corp Plc Business Overview
- 4.4.3 Prothena Corp Plc Alpha Synuclein Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Prothena Corp Plc Alpha Synuclein Product Portfolio
- 4.4.5 Prothena Corp Plc Recent Developments
- 4.5 nLife Therapeutics SL
- 4.5.1 nLife Therapeutics SL Company Information
- 4.5.2 nLife Therapeutics SL Business Overview
- 4.5.3 nLife Therapeutics SL Alpha Synuclein Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 nLife Therapeutics SL Alpha Synuclein Product Portfolio
- 4.5.5 nLife Therapeutics SL Recent Developments
- 4.6 Neuropore Therapies Inc
- 4.6.1 Neuropore Therapies Inc Company Information
- 4.6.2 Neuropore Therapies Inc Business Overview
- 4.6.3 Neuropore Therapies Inc Alpha Synuclein Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Neuropore Therapies Inc Alpha Synuclein Product Portfolio
- 4.6.5 Neuropore Therapies Inc Recent Developments
- 4.7 MedImmune LLC
- 4.7.1 MedImmune LLC Company Information
- 4.7.2 MedImmune LLC Business Overview
- 4.7.3 MedImmune LLC Alpha Synuclein Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 MedImmune LLC Alpha Synuclein Product Portfolio
- 4.7.5 MedImmune LLC Recent Developments
- 4.8 ICB International Inc
- 4.8.1 ICB International Inc Company Information
- 4.8.2 ICB International Inc Business Overview
- 4.8.3 ICB International Inc Alpha Synuclein Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 ICB International Inc Alpha Synuclein Product Portfolio
- 4.8.5 ICB International Inc Recent Developments
- 4.9 H. Lundbeck A/S
- 4.9.1 H. Lundbeck A/S Company Information
- 4.9.2 H. Lundbeck A/S Business Overview
- 4.9.3 H. Lundbeck A/S Alpha Synuclein Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 H. Lundbeck A/S Alpha Synuclein Product Portfolio
- 4.9.5 H. Lundbeck A/S Recent Developments
- 4.10 Genmab A/S
- 4.10.1 Genmab A/S Company Information
- 4.10.2 Genmab A/S Business Overview
- 4.10.3 Genmab A/S Alpha Synuclein Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Genmab A/S Alpha Synuclein Product Portfolio
- 4.10.5 Genmab A/S Recent Developments
- 4.11 Evotec AG
- 4.11.1 Evotec AG Company Information
- 4.11.2 Evotec AG Business Overview
- 4.11.3 Evotec AG Alpha Synuclein Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Evotec AG Alpha Synuclein Product Portfolio
- 4.11.5 Evotec AG Recent Developments
- 4.12 BioArctic AB
- 4.12.1 BioArctic AB Company Information
- 4.12.2 BioArctic AB Business Overview
- 4.12.3 BioArctic AB Alpha Synuclein Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 BioArctic AB Alpha Synuclein Product Portfolio
- 4.12.5 BioArctic AB Recent Developments
- 4.13 AFFiRiS AG
- 4.13.1 AFFiRiS AG Company Information
- 4.13.2 AFFiRiS AG Business Overview
- 4.13.3 AFFiRiS AG Alpha Synuclein Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 AFFiRiS AG Alpha Synuclein Product Portfolio
- 4.13.5 AFFiRiS AG Recent Developments
- 4.14 AC Immune SA
- 4.14.1 AC Immune SA Company Information
- 4.14.2 AC Immune SA Business Overview
- 4.14.3 AC Immune SA Alpha Synuclein Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 AC Immune SA Alpha Synuclein Product Portfolio
- 4.14.5 AC Immune SA Recent Developments
5 Global Alpha Synuclein Market Scenario by Region
- 5.1 Global Alpha Synuclein Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Alpha Synuclein Sales by Region: 2021-2032
- 5.2.1 Global Alpha Synuclein Sales by Region: 2021-2026
- 5.2.2 Global Alpha Synuclein Sales by Region: 2027-2032
- 5.3 Global Alpha Synuclein Revenue by Region: 2021-2032
- 5.3.1 Global Alpha Synuclein Revenue by Region: 2021-2026
- 5.3.2 Global Alpha Synuclein Revenue by Region: 2027-2032
- 5.4 North America Alpha Synuclein Market Facts & Figures by Country
- 5.4.1 North America Alpha Synuclein Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Alpha Synuclein Sales by Country (2021-2032)
- 5.4.3 North America Alpha Synuclein Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Alpha Synuclein Market Facts & Figures by Country
- 5.5.1 Europe Alpha Synuclein Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Alpha Synuclein Sales by Country (2021-2032)
- 5.5.3 Europe Alpha Synuclein Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Alpha Synuclein Market Facts & Figures by Country
- 5.6.1 Asia Pacific Alpha Synuclein Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Alpha Synuclein Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Alpha Synuclein Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Alpha Synuclein Market Facts & Figures by Country
- 5.7.1 South America Alpha Synuclein Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Alpha Synuclein Sales by Country (2021-2032)
- 5.7.3 South America Alpha Synuclein Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Alpha Synuclein Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Alpha Synuclein Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Alpha Synuclein Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Alpha Synuclein Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Alpha Synuclein Sales by Type (2021-2032)
- 6.1.1 Global Alpha Synuclein Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Alpha Synuclein Sales Market Share by Type (2021-2032)
- 6.2 Global Alpha Synuclein Revenue by Type (2021-2032)
- 6.2.1 Global Alpha Synuclein Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Alpha Synuclein Revenue Market Share by Type (2021-2032)
- 6.3 Global Alpha Synuclein Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Alpha Synuclein Sales by Application (2021-2032)
- 7.1.1 Global Alpha Synuclein Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Alpha Synuclein Sales Market Share by Application (2021-2032)
- 7.2 Global Alpha Synuclein Revenue by Application (2021-2032)
- 7.2.1 Global Alpha Synuclein Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Alpha Synuclein Revenue Market Share by Application (2021-2032)
- 7.3 Global Alpha Synuclein Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Alpha Synuclein Value Chain Analysis
- 8.1.1 Alpha Synuclein Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Alpha Synuclein Production Mode & Process
- 8.2 Alpha Synuclein Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Alpha Synuclein Distributors
- 8.2.3 Alpha Synuclein Customers
9 Global Alpha Synuclein Analyzing Market Dynamics
- 9.1 Alpha Synuclein Industry Trends
- 9.2 Alpha Synuclein Industry Drivers
- 9.3 Alpha Synuclein Industry Opportunities and Challenges
- 9.4 Alpha Synuclein Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst